Cross-source evidence timeline

Zilucoplan research timeline

Follow 25 selected, directly cited source records from December 20, 2021 through November 5, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

25Selected records
6Source years
3Evidence lanes
November 5, 2026Latest source date

Source year

2026

13 records
  1. Clinical trials

    ClinicalTrials.gov record NCT06055959↗

    PeptideScanner retained ClinicalTrials.gov record NCT06055959 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

  2. Literature metadata

    Zilucoplan as a rescue therapy in myasthenic crisis: a case description and summary of early report experiences.↗

    PubMed lists PMID 42467314 in Acta neurologica Belgica as Letter, with publication-date metadata of 2026-07-17 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT06435312↗

    PeptideScanner retained ClinicalTrials.gov record NCT06435312 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT07215949↗

    PeptideScanner retained ClinicalTrials.gov record NCT07215949 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT06961747↗

    PeptideScanner retained ClinicalTrials.gov record NCT06961747 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

  6. Literature metadata

    A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis.↗

    PubMed lists PMID 42604018 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT04297683↗

    PeptideScanner retained ClinicalTrials.gov record NCT04297683 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

  8. Literature metadata

    Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.↗

    PubMed lists PMID 41314023 in Journal of the neurological sciences as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT06471361↗

    PeptideScanner retained ClinicalTrials.gov record NCT06471361 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

  10. Literature metadata

    Letter to the editor: Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.↗

    PubMed lists PMID 41604997 in Journal of the neurological sciences as Letter, with publication-date metadata of 2026-01-23 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Letter to editor: Early real-life experience on zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.↗

    PubMed lists PMID 41653661 in Journal of the neurological sciences as Letter, with publication-date metadata of 2026-01-22 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Manifestation of morphea in a patient with myasthenia gravis under therapy with zilucoplan.↗

    PubMed lists PMID 41058183 in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG as Case Reports, Journal Article, with publication-date metadata of 2025-10-07 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  13. Clinical trials

    ClinicalTrials.gov record NCT06511076↗

    PeptideScanner retained ClinicalTrials.gov record NCT06511076 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-01-06, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

Source year

2025

4 records
  1. Clinical trials

    ClinicalTrials.gov record NCT06815133↗

    PeptideScanner retained ClinicalTrials.gov record NCT06815133 at 2026-11-15T21:46:36.651Z. Its registry update date was 2025-12-03, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

  2. Literature metadata

    Zilucoplan as a fast-acting treatment for severe myasthenic exacerbation: A case series.↗

    PubMed lists PMID 40685269 in Revue neurologique as Letter, with publication-date metadata of 2025-07-19 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Regulatory

    Federal Register notice 2025-11314↗

    The Federal Register published notice 2025-11314, attributed to FDA and its parent HHS department, on 2025-06-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZILBRYSQ,” and PeptideScanner's exact reviewed identity mapping connects the document to Zilucoplan.↗

  4. Regulatory

    Federal Register notice 2025-09068↗

    The Federal Register published notice 2025-09068, attributed to FDA and its parent HHS department, on 2025-05-21. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Zilucoplan.↗

Source year

2024

3 records
  1. Literature metadata

    Usability of the zilucoplan prefilled syringe for the treatment of generalized myasthenia gravis: insights from a human factors validation study.↗

    PubMed lists PMID 39403865 in Expert review of medical devices as Journal Article, Validation Study, with publication-date metadata of 2024-10-15 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria.↗

    PubMed lists PMID 37534517 in Haematologica as Clinical Trial, Phase II, Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-03-01 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Zilucoplan (Zilbrysq) for myasthenia gravis.↗

    PubMed lists PMID 38576149 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2023

3 records
  1. Regulatory

    Drugs@FDA application NDA216834↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 216834 with status AP dated 2023-10-17, and names zilucoplan sodium among the application record's active ingredients.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT04382755↗

    PeptideScanner retained ClinicalTrials.gov record NCT04382755 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-09-14, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT04436497↗

    PeptideScanner retained ClinicalTrials.gov record NCT04436497 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-07-25, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

Source year

2022

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT04590586↗

    PeptideScanner retained ClinicalTrials.gov record NCT04590586 at 2026-11-15T21:46:36.651Z. Its registry update date was 2022-06-29, and PeptideScanner's reviewed identity mapping was zilucoplan.↗

Source year

2021

1 record
  1. Literature metadata

    Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan.↗

    PubMed lists PMID 33398524 in Amino acids as Journal Article, with publication-date metadata of 2021-01-04 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗